Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Restructuring Costs (2020 - 2025)

Historic Restructuring Costs for BioNexus Gene Lab (BGLC) over the last 6 years, with Q3 2025 value amounting to $445691.0.

  • BioNexus Gene Lab's Restructuring Costs fell 4375.52% to $445691.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 62541.51%. This contributed to the annual value of $2.0 million for FY2024, which is 1919.42% down from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Restructuring Costs is $445691.0, which was down 4375.52% from $516790.0 recorded in Q2 2025.
  • BioNexus Gene Lab's Restructuring Costs' 5-year high stood at $3.1 million during Q3 2023, with a 5-year trough of -$2.0 million in Q4 2023.
  • For the 5-year period, BioNexus Gene Lab's Restructuring Costs averaged around $462014.4, with its median value being $418824.0 (2022).
  • The largest annual percentage gain for BioNexus Gene Lab's Restructuring Costs in the last 5 years was 63590.05% (2023), contrasted with its biggest fall of 50651.62% (2023).
  • Over the past 5 years, BioNexus Gene Lab's Restructuring Costs (Quarter) stood at $182831.0 in 2021, then surged by 166.84% to $487858.0 in 2022, then crashed by 506.52% to -$2.0 million in 2023, then skyrocketed by 115.48% to $306932.0 in 2024, then skyrocketed by 45.21% to $445691.0 in 2025.
  • Its Restructuring Costs stands at $445691.0 for Q3 2025, versus $516790.0 for Q2 2025 and $391876.0 for Q1 2025.